{"title":"A first case report of using chimeric antigen receptor T-cell immunotherapy to treat high-risk smoldering multiple myeloma.","authors":"Yang Liu, Wenbing Duan, Xiaojun Huang, Jin Lu","doi":"10.2478/jtim-2023-0097","DOIUrl":null,"url":null,"abstract":"Smoldering multiple myeloma (SMM) is now considered a heterogeneous set of diseases with different tendencies to progress to active myeloma. Several trials aimed at curing multiple myeloma (MM) in the smoldering stage through intensive treatment have reported effective control of active myeloma.[1] At the same time, Chimeric antigen receptor (CAR) T-cell immunotherapy is currently being intensively tested for treating relapsed and refractory myeloma.[2] Here, we report a patient with smoldering myeloma who elected to be treated with CAR T-cell therapy and has now achieved minimal residual disease (MRD) negativity.","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"11 3","pages":"294-296"},"PeriodicalIF":4.7000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474885/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Translational Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/jtim-2023-0097","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Smoldering multiple myeloma (SMM) is now considered a heterogeneous set of diseases with different tendencies to progress to active myeloma. Several trials aimed at curing multiple myeloma (MM) in the smoldering stage through intensive treatment have reported effective control of active myeloma.[1] At the same time, Chimeric antigen receptor (CAR) T-cell immunotherapy is currently being intensively tested for treating relapsed and refractory myeloma.[2] Here, we report a patient with smoldering myeloma who elected to be treated with CAR T-cell therapy and has now achieved minimal residual disease (MRD) negativity.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
